Glucotrack (Nasdaq:GCTK) today said it hit a significant milestone in the development of its continuous blood glucose monitor (CBGM).
Our sister site, Drug Delivery Business News, reports today that Glucotrack completed the first-in-human study of its CBGM.
Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. It aims to provide real-time readings without the lag time the company says is typically associated with interstitial glucose measurements. Glucotrack’s long-term implantable device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution.
Glucotrack says the study had the first real-time CBGM placed in the subclavian vein. It met its primary endpoint with no procedure- or device-related serious adverse events from implant through seven days post-removal. The study also confirmed the function of the CBGM sensor lead in the subclavian bein.
Get the full story at our sister site, Drug Delivery Business News.